牛牛AI助理已提取核心訊息
AbbVie Inc. officer, Azita Saleki-Gerhardt, is set to sell 52,870 shares of the company's common stock on February 21, 2024, according to a recent filing. The shares, valued at approximately $9,184,486.84, were acquired on the same date through a stock option exercise as part of compensation from the issuer. This transaction follows a period where no significant sales activity was reported by Saleki-Gerhardt in the past three months.
AbbVie Inc. officer, Azita Saleki-Gerhardt, is set to sell 52,870 shares of the company's common stock on February 21, 2024, according to a recent filing. The shares, valued at approximately $9,184,486.84, were acquired on the same date through a stock option exercise as part of compensation from the issuer. This transaction follows a period where no significant sales activity was reported by Saleki-Gerhardt in the past three months.
根據最近的一份文件，艾伯維公司高管阿齊塔·薩利基·格哈特定於2024年2月21日出售該公司52,870股普通股。這些股票價值約9,184,486.84美元，是作爲發行人薪酬的一部分，於同日通過股票期權行使收購。此次交易是在Saleki-Gerhardt在過去三個月中沒有報告任何重大銷售活動之後進行的。
根據最近的一份文件，艾伯維公司高管阿齊塔·薩利基·格哈特定於2024年2月21日出售該公司52,870股普通股。這些股票價值約9,184,486.84美元，是作爲發行人薪酬的一部分，於同日通過股票期權行使收購。此次交易是在Saleki-Gerhardt在過去三個月中沒有報告任何重大銷售活動之後進行的。
有用
沒用